Explore more publications!

Tech Journal of Mauritius: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Journal of Mauritius.

Press releases published on February 9, 2026

Helsinn and ESTEVE expand their partnership extending the Distribution and Licence Agreement for AKYNZEO® and ALOXI® to Austria
Aerospike Database’s New Native Dynamic Data Masking Simplifies PII Protection and Regulatory Compliance
WorldWiDE EdTech Awards 2026 Winners Announced
Lantronix begegnet Netzwerkausfällen mit automatisierten Out-of-Band-Innovationen auf der Cisco Live 2026 in Amsterdam
Lantronix Tackles Network Downtime With Automated Out-of-Band Innovations at Cisco Live 2026 Amsterdam
Lantronix pakt netwerkuitval aan met geautomatiseerde out-of-band-innovaties tijdens Cisco Live 2026 in Amsterdam
Strong clinical data for Breye Therapeutics’ lead oral asset danegaptide presented at Angiogenesis, Exudation and Degeneration 2026 symposium
Aptean Unveils Aptean Intelligence as a Service, Delivering Industry‑Ready AI Agents That Drive Real Operational Results
Memo Therapeutics AG Enters into a Collaboration and Option Agreement with CSL for Development of Recombinant Polyclonal IgG Technology
Gute Verkaufszahlen für Cresemba® (Isavuconazol) in der Region Asien-Pazifik und China lösen Meilensteinzahlung an Basilea aus
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
Communiqué de presse: Le rilzabrutinib de Sanofi a été désigné comme thérapie innovante aux États-Unis et comme médicament orphelin au Japon pour le traitement de l’anémie hémolytique auto-immune à anticorps chauds
Press Release: Sanofi’s rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia
WISeKey’s WISe.Art and GMA Once Again Revolutionize the Future of Art and Technology in an Extraordinary Event in Venice
InnoCare Announces IND Approval to Initiate Clinical Trial of VAV1 Degrader ICP-538 in China
Digital Realty Debuts NVIDIA Certification for Liquid Cooled Data Center in Japan
Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Designated for Priority Review in China

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions